

Research article

Open Access

Molecular epidemiology of drug-resistant malaria in western Kenya highlands

Daibin Zhong*¹, Yaw Afrane², Andrew Githeko², Liwang Cui³,
David M Menge⁴ and Guiyun Yan¹

Address: ¹Program in Public Health, College of Health Sciences, University of California at Irvine, Irvine, CA 92697, USA, ²Center for Vector Biology and Control Research, Kenya Medical Research Institute, Kisumu, Kenya, ³Department of Entomology, the Pennsylvania State University, University Park, PA 16802, USA and ⁴Center for Infectious Diseases and Microbiology Translational Research, University of Minnesota, Minneapolis, MN 55455, USA

Email: Daibin Zhong* - dzhong@uci.edu; Yaw Afrane - yaw_afrane@yahoo.com; Andrew Githeko - agitheko1@kisian.mimcom.net; Liwang Cui - luc2@psu.edu; David M Menge - menge023@umn.edu; Guiyun Yan - guiyun@uci.edu

* Corresponding author

Published: 31 July 2008

Received: 2 April 2008

BMC Infectious Diseases 2008, 8:105 doi:10.1186/1471-2334-8-105

Accepted: 31 July 2008

This article is available from: <http://www.biomedcentral.com/1471-2334/8/105>

© 2008 Zhong et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Since the late 1980s a series of malaria epidemics has occurred in western Kenya highlands. Among the possible factors that may contribute to the highland malaria epidemics, parasite resistance to antimalarials has not been well investigated.

Methods: Using parasites from highland and lowland areas of western Kenya, we examined key mutations associated with *Plasmodium falciparum* resistance to sulfadoxine – pyrimethamine and chloroquine, including dihydrofolate reductase (*pfdhfr*) and dihydropteroate synthetase (*pfdhps*), chloroquine resistance transporter gene (*pfcr*), and multi-drug resistance gene 1 (*pfmdr1*).

Results: We found that >70% of samples harbored 76T *pfcr* mutations and over 80% of samples harbored quintuple mutations (511/59R/108N *pfdhfr* and 437G/540E *pfdhps*) in both highland and lowland samples. Further, we did not detect significant difference in the frequencies of these mutations between symptomatic and asymptomatic malaria volunteers, and between highland and lowland samples.

Conclusion: These findings suggest that drug resistance of malaria parasites in the highlands could be contributed by the mutations and their high frequencies as found in the lowland. The results are discussed in terms of the role of drug resistance as a driving force for malaria outbreaks in the highlands.

Background

Malaria is a major public health problem in sub-Saharan Africa and *Plasmodium falciparum* infection is a leading cause of morbidity and mortality inflicting a huge economic burden in countries where the disease is endemic [1]. It is estimated that death toll of malaria exceeds one

million people each year, and the victims are primarily children under the age of five [2]. Until the early 1980s, the African highlands (generally referred to areas of >1,500 m above sea level) were either free of malaria or had very low incidences of the disease; however, since the late 1980s a series of malaria epidemics has occurred [3-

9]. Among the many factors that may contribute to the highland malaria epidemics, resistance of the parasites to multiple antimalarials has not been extensively investigated. Resistance to antimalarial drugs is one of the major obstacles for effective malaria control. The first case of chloroquine (CQ) resistance in Kenya was reported in 1977 [10]. In 1993, resistance levels had reached 70% [11]. In 1998, the Ministry of Health of Kenya changed the first line of treatment from chloroquine to sulfadoxine – pyrimethamine (SP; Fansidar®) [12]. In 2004, the Ministry of Health of Kenya officially changed the first-line drug to artemether/lumefantrin (Coartem™) [13].

Drug resistance in malaria parasites is associated with genetic mutations in target genes and can be monitored using molecular methods. CQ resistance is determined by the major point mutation at codon 76 of the *P. falciparum* CQ resistance transporter (*pfcr*) gene [14], which is highly correlated with increased clinical CQ tolerance and treatment failure [14-16]. In addition, point mutations in *P. falciparum* multi-drug resistance gene 1 (*pfmdr1*) (e.g., N86Y, Y183F, S1034C, N1042D, and D1246Y) have been shown to modulate CQ resistance [17] and possibly lumefantrine resistance [18]. Resistance to antifolates is associated with point mutations in the dihydrofolate reductase (*pfdhfr*) and dihydropteroate synthetase (*pfdhps*) genes [19]. Pyrimethamine (PY) resistance is conferred by the key mutation at codon 108 in the *pfdhfr* gene, while additional mutations at positions 51 and 59 increase the levels of resistance [20]. The 164L mutation common in South-east Asia has been shown to confer PY resistance. Although this mutation is not common in Africa, a recent study by McCollin et al detected the 164L mutation in western Kenya [21]. Similarly, sulfadoxine (SD) resistance is conferred by a key mutation at codon 437 in the *pfdhps* gene and modulated by additional mutations at codons 436, 540, 581, and 613 [22]. Multiple mutations in these two genes result in antifolate treatment failure [23]. Molecular methods have been developed to detect point mutations in genes responsible for drug resistance [24-26], and have been widely used to monitor drug resistance in epidemiological surveys [16]. In this study, we have analyzed the mutations of antimalarial drug resistance genes for CQ (*pfcr* and *pfmdr1*) and antifolates (*pfdhps* and *pfdhfr*) in samples from patients with acute malaria infections and school children with asymptomatic infections at one lowland and two highland locations in western Kenya.

Methods

Sample collection

Sampling in two highland sites (Kisii, elevation ~1600 m above sea level; and Kakamega, elevation 1,480–1,560 m) and one neighboring lowland site (Kombewa, elevation ~1200 m) from June through August 2005 were con-

ducted as a part of malaria surveillance activities. Average annual malaria prevalence among primary school children during the sampling period was 10.3%, 42.7% and 75% in Kisii, Kakamega and Kombewa, respectively. Malaria transmission intensity, measured by entomological inoculation rate (EIR), was 0.4, 16.6 and 31.1 infectious bites per person per year in Kisii, Kakamega and Kombewa, respectively [27]. At each site, 100 samples were collected from patients admitted with acute *P. falciparum* infection at a local hospital and 100 samples from primary school children (age 6–14 years old) with asymptomatic *P. falciparum* infections diagnosed by microscopy. Symptomatic malaria patients were treated by clinicians in the hospital with antimalarial drug, Coartem which achieved cure rates of up to 95%, even in areas of multi-drug resistance. Each sample consisted of ~200 µl of finger-prick blood spotted on filter papers. Filter papers were dried and stored at -20°C until parasite DNA extraction. The human subject protocol involved in this study has been approved by University of California, Irvine (UCI) and Kenya Medical Research Institute (KEMRI). Informed consent was provided by the parents/guardians of the children and assent from the children was obtained prior to the sample collection.

Parasite DNA extraction and species identification

DNA was extracted from the blood filters using the Saponin/Chelex method [28]. Parasite DNA was extracted from one quarter of a blood spot of about 1 cm in diameter and dissolved in 200 µl of distilled water. Three microliters of the parasite DNA were used as the template for polymerase chain reaction (PCR). To avoid complications from mixed parasite species infections, a nested PCR method was used to verify *P. falciparum* infections and exclude the presence of other *Plasmodium* species in each sample [29]. Approximately 3–5% of samples containing mixed parasite species or other parasite species were identified in all the study sites. Samples containing only *P. falciparum* DNA were used for genotyping analysis.

Molecular detection of mutations in drug targets

Mutations in the *pfcr* (K76T) and *pfmdr1* genes were detected using a PCR-restriction fragment length polymorphism (RFLP) method. The fragment encompassing *pfcr* codon 76 was amplified and digested with *ApoI*, which cleaves the wild type into 111 and 34 bp fragments [30]. Similarly, fragments containing codons 86, 184, 1034, 1042, and 1246 of the *pfmdr1* gene were separately amplified by PCR and digested with respective restrictive enzymes as described previously [30-33]. Screening for mutations associated with antifolate resistance at codons 16, 50, 51, 59, 108, and 164 of the *pfdhfr* gene and codons 436, 437, 540, 581, and 613 of the *pfdhps* gene was performed by nested PCR and mutation-specific restriction enzyme digestions [34-36].

Statistical analysis

The difference in frequencies of point mutations in the four aforementioned genes between highland and lowland parasite populations was determined by using the χ^2 tests or Fisher's exact test for datasets with sample size less than 5. Yates' correction was applied for the chi-square value, resulting in corrected *P* values. Statistical significance was taken at the *P* = 0.05 level. Association between the different mutations was tested using Fisher's exact test.

Results

A total of 600 *P. falciparum* samples were analyzed for *pfcr*, *pfmdr1*, *pfdhfr*, and *pfdhps* genes. Over 90% of samples were successfully amplified at the 17 test codons, and polymorphisms were detected at 10 of 17 codons screened (Table 1). Consistent with the hyperendemic settings in the study areas, we detected infections by mixed strains at seven of the 17 studied codons, which included

codon 76 of *pfcr*, codons 86, 184 and 1246 of *pfmdr1*, codon 59 of *pfdhfr*, and codons 437 and 540 of *pfdhps* (Table 1). The frequencies of mutant codons at the four genes varied slightly between the study sites, but the differences were not significant (Fig. 1). Mixed-genotype infections at *pfdhfr* codon 59, 437, and 540 of the antifolate target genes were low (<10%) in all samples. Similarly, mixed-genotype infections at codon 76 of the *pfcr* gene were low (<15%). In contrast, mixed-genotype infections at codons 86, 184 and 1246 of the *pfmdr1* gene were more frequent (18 – 45%) (Table 1).

Mutations in CQ resistance genes

Consistent with the past extensive use of CQ in this area, the *pfcr* 76T mutant allele was present in = 80% (including mixed infections with wild type and mutant alleles) of all samples from the three locations (Fig. 1A and 1B). In comparison, mutations at alleles 86Y, 184F and 1246Y of

Table 1: Frequencies of mutations in genes associated with resistance to chloroquine, sulfadoxine-pyrimethamine in *P. falciparum* parasites from symptomatic and asymptomatic volunteers in western Kenya.

Gene	Mutation	Polymorphism	Kombewa		Kakamega		Kisii	
			S*	A*	S	A	S	A
<i>pfcr</i>	K76T	Mutant	87	81	86	77	75	70
		Mixed	7	15	6	9	8	10
		Wild-type	6	4	8	14	17	20
<i>Pfmdr1</i>	N86Y	Mutant	28	41	28	39	10	23
		Mixed	44	22	45	37	40	18
		Wild-type	28	37	27	24	50	59
	Y184F	Mutant	24	15	7	5	11	26
		Mixed	26	30	23	26	33	19
		Wild-type	50	55	70	69	56	55
D1246Y	Mutant	24	37	40	28	42	24	
	Mixed	42	30	36	44	21	29	
	Wild-type	34	33	24	28	37	47	
<i>pfdhfr</i>	N51I	Mutant	98	96	98	98	96	95
		Mixed	0	0	0	0	0	0
		Wild-type	2	4	2	2	4	5
	C59R	Mutant	81	75	88	79	90	86
		Mixed	4	10	2	7	2	0
		Wild-type	15	15	10	14	8	14
S108N	Mutant	100	100	100	100	100	100	
	Mixed	0	0	0	0	0	0	
	Wild-type	0	0	0	0	0	0	
<i>pfdhps</i>	S436F	Mutant	4	2	4	4	2	2
		Mixed	0	0	0	0	0	0
		Wild-type	96	98	96	96	98	98
	A437G	Mutant	94	95	92	93	88	93
		Mixed	4	5	4	7	2	0
		Wild-type	2	0	4	0	10	7
	K540E	Mutant	88	95	92	91	88	93
		Mixed	10	5	4	9	2	0
		Wild-type	2	0	4	0	10	7

* S – symptomatic; A – asymptomatic.

Note: No mutations were detected at the following codons: *pfdhfr* (A16V, C50R and I164L); *pfdhps* (S436A, A581G and A613S); and *pfmdr1* (S1034 and N1042D).




Figure 1
 Frequency of mutations in *Plasmodium falciparum* chloroquine resistance transporter gene (*pfcr*) (A and B), multi-drug resistance gene (*pfmdr1*) (C and D) and quintuple mutations in dihydrofolate reductase (*pfdhfr*)/dihydropteroate synthetase (*pfdhps*) (E and F) genes in symptomatic and asymptomatic volunteers in highland (Kakamega and Kisii) and lowland (Kombewa) sites of western Kenya. The *pfdhfr/pfdhps* quintuple mutation refers to 51I/59R/108N/437G/540E. No mutations were detected at the following codons: *pfdhfr* (A16V, C50R, I164L and S436A), *pfdhps* (A581G and A613S), and *pfmdr1* (S1034 and N1042D).

pfmdr1 gene were present at lower frequencies, ranging from 30 to 76% (including mixed infections) (Fig. 1C and 1D), whereas no mutation was found at codons 1034 and 1042, which was associated with CQ resistance in South America. The frequencies of mutations were generally not significantly different between the three study sites except *pfcr* 76T and *pfmdr1* 86Y between Kombewa and Kisii ($P < 0.05$), and *pfmdr1* 184F between Kombewa and Kakamega ($P < 0.01$) (Fig. 1E and 1F). Consequently, the genotype 86Y/184Y/1246Y (wildtype at codon 184) was present at a significantly higher frequency in highland than in lowland parasites ($P < 0.05$), whereas the genotype 86Y/184F/1246Y (triple mutations) was significantly more frequent in lowland than in highland parasites (Table 2). Since certain *pfmdr1* alleles were found associated with CQ resistance, we compared the association between *pfmdr1* mutations and the major CQ-resistance determinant *pfcr* 76T. When all parasite samples were

Table 2: Percentage of haplotypes of *P. falciparum* parasites collected from symptomatic and asymptomatic volunteers in western Kenya.

Haplotypes	Kombewa		Kakamega		Kisii	
	S*	A*	S	A	S	A
<i>Pfmdr1</i>						
86Y/184Y/1246Y	24	26	44	46	38	36
86Y/184E/1246Y	32	34	24	23	16	13
86N/184E/1246D	12	15	0	0	25	27
86Y/184F/1246D	18	10	0	5	1	0
86Y/184Y/1246D	2	0	16	10	1	3
86N/184Y/1246D	6	5	8	10	11	12
86N/184E/1246Y	3	5	4	3	8	5
86N/184Y/1246Y	3	5	4	3	0	4
<i>Pfdhfr/pfdhps</i>						
Quintuple						
51I/59R/108N/437G/540E	87	84	86	83	85	80
Quadruple						
51I/59C/108N/437G/540E	7	5	3	8	4	4
51N/59R/108N/437G/540E	0	0	4	3	2	6
51I/59R/108N/437G/540K	1	5	1	2	1	2
51I/59R/108N/437A/540E	1	1	0	0	3	4
Triple						
51I/59R/108N/437A/540K	2	3	2	2	5	4
Double						
51I/59C/108N/437A/540K	2	2	4	2	0	0

* S – symptomatic; A – asymptomatic; The mutation amino acids are underlined.

taken into account, significant associations were found between the *pfcr* 76T and two *pfmdr1* alleles (184F and 1246Y) ($P < 0.01$). However, *pfcr* 76T was not significantly associated with *pfmdr1* 86Y ($P = 0.174$), the mutation found associated with CQ-resistant field isolates in Asia and Africa.

Mutations in antifolate drug resistance genes

Despite relatively recent deployment of antifolate drugs for controlling malaria in western Kenya, parasites with mutations in the drug target genes, *pfdhfr* and *pfdhps*, were highly prevalent. The mutation at codon 108 (allele 108N) of the *pfdhfr* gene, a major determinant of PY resistance, was ubiquitously present in all samples (Table 1). In addition, mutant alleles at codons 51 and 59 were also detected at high frequencies (85% – 98%). No mutation was detected at codons 16, 50, and 164 of *pfdhfr*. Most samples (90% – 100%) contained the key SD-resistance determinant mutation A437G and K540E in *pfdhps*. In contrast, the mutant 436F allele was rare (< 5%), and mutant 436A allele was not detected in any locations. Further, no mutation was detected at codons 581 and 613 of *pfdhps*.

Increased numbers of mutations at the two antifolate target genes are associated with increased resistance to SD-

PY. In the studied samples, single or double mutations were rarely encountered, whereas triple mutations in the *pfdhfr* gene were the most common. When the two genes were combined, quintuple mutations (51I/59R/108N of *pfdhfr* and 437G/540E of *pfdhps*) were found with a high prevalence (80–87%) at the three sites (Fig. 1E and 1F), followed by quadruple mutations (51I/59C/108N/437G/540E, 51N/59R/108N/437G/540E, 51I/59R/108N/437G/540K, 51I/59R/108N/437A/540E) (8% – 16%) (Table 2).

Mutation frequency difference between asymptomatic and symptomatic samples

The *pfcr* K76T mutation frequencies were not significantly different in the asymptomatic and symptomatic samples in the lowland Kombewa site (96% vs. 94%; Fisher's exact test, $P = 0.537$) and two highland sites (86% vs. 92% in Kakamega, $\chi^2 = 1.41$, $df = 1$, $P = 0.235$; 80% vs. 83% in Kisii, $\chi^2 = 0.03$, $df = 1$, $P = 0.863$). Similarly, there was no significant difference in mutation frequencies of *pfmdr1* gene at test codons between asymptomatic and symptomatic samples in the lowland (Kombewa: $\chi^2 = 1.44$, $df = 1$, $P = 0.230$ at codon N86Y; $\chi^2 = 0.33$, $df = 1$, $P = 0.566$ at codon Y184F; $\chi^2 = 0$, $df = 1$, $P = 1.000$ at codon D1246Y) and two highland sites (Kakamega: $\chi^2 = 0.07$, $df = 1$, $P = 0.791$ at codon N86Y; $\chi^2 = 0.01$, $df = 1$, $P = 0.920$ at codon Y184F; $\chi^2 = 0.26$, $df = 1$, $P = 0.610$ at codon D1246Y. Kisii: $\chi^2 = 0.87$, $df = 1$, $P = 0.351$ at codon N86Y; $\chi^2 = 0$, $df = 1$, $P = 1.000$ at codon Y184F; $\chi^2 = 1.40$, $df = 1$, $P = 0.237$ at codon D1246Y). Similarly, for the *pfdhfr/pfdhps* quintuple mutation frequencies, no significant difference was found in the asymptomatic and symptomatic samples in both lowland site (Kombewa: $\chi^2 = 0.16$, $df = 1$, $P = 0.689$) and highland sites (Kakamega: $\chi^2 = 0.20$, $df = 1$, $P = 0.655$. Kisii: $\chi^2 = 0.32$, $df = 1$, $P = 0.572$).

Discussion

In the present study, we analyzed the mutations of four known drug resistance genes in both highland and lowland parasite populations of western Kenya. We showed that the frequencies of key mutations in the *pfcr*, *pfmdr1*, *pfdhps*, and *pfdhfr* genes that were implicated in resistance to CQ and SP were very high. We further demonstrated that there was no difference in the frequencies of key mutations between symptomatic and asymptomatic malaria volunteers. Our experiment design did not allow us to test clinical or parasitological efficacy in symptomatic infections after treatment; nor was the mutation prevalence/in vivo resistance before 1998 when the national policies of treating uncomplicated malaria were changed to SP was examined. Nevertheless, the big sample size in this study coupled to lack of differences in the frequency of resistant parasite genotypes in the two highland areas and the low land area clearly demonstrates a high frequency of drug resistant mutants circulating in the study areas.

Resistance to CQ is largely determined by the K76T mutation in the *pfcr* gene, and enhanced by mutations at other sites of this gene and mutations in the *pfmdr1* gene. Since resistant phenotypes often have fitness costs [37], their prevalence is expected to decline after removal of the selective pressure. For example, the prevalence of mutant alleles of *pfcr* 76T decreased from 64.5% in 2002 to 16% in 2004 and that of mutant *pfmdr1* 86Y alleles decreased from 46.6% to 2.7% two and half year after CQ withdrawal in coastal Tanzania [38]. Kublin et al. reported that the prevalence of the chloroquine-resistant *pfcr* 76T genotype decreased from 85% in 1992 to 13% in 2000. In 2001, chloroquine cleared 100% of 63 asymptomatic *P. falciparum* infections, no isolates were resistant to chloroquine in vitro, and no infections with the chloroquine-resistant *pfcr* 76T genotype were detected [39]. Similarly, Laufer et al. demonstrated that chloroquine was again an efficacious treatment for malaria, 12 years after it was withdrawn from use in Malawi [40]. Although Kenya had a similar drug policy, the *pfcr* K76T mutation in western Kenya was still predominant. Consistent with the observation of high *pfcr* K76T mutation frequency in the study sites, *pfmdr1* mutations that enhance CQ resistance (e.g., 86Y) were also present at relatively high frequencies (37.2 – 45.2%) in western Kenya. This may be partly caused by wide availability and consumption of CQ after it was replaced as first-line antimalarial drug by antifolate drug (SP) in 1998 [12,13]. Our results indicated that parasite populations in western Kenya were still highly resistant to 4-aminoquinoline drugs.

Several years after introduction of SP as the first-line antimalarial drug in Kenya, mutant genotypes have already become common. We found that mutations at codon 108 of the *pfdhfr* gene and codon 437 of the *pfdhps* gene, which are the major determinants for sulfadoxine and pyrimethamine resistance, respectively, were highly prevalent in our study sites. Furthermore, increased resistance to antifolate drugs was correlated with mutations at additional sites, which were also detected in our present study. In Kenya, Nzila et al. [41] reported that the *pfdhfr* triple mutant (codons 108, 51 and 59) was associated with seven-day treatment failure using Fansidar, and this association was strengthened by the presence of double mutations of the *pfdhps* gene at codons 437 and 540. Such "quintuple" mutants were also strongly correlated with Fansidar treatment failure in Malawi [26]. These quintuple mutants have already reached 80–87% prevalence in the parasite populations in western Kenya. This is consistent with the observation in another highland site in Chogoria, near Mount Kenya [42]. Since mutations at different sites of the *pfdhfr* and *pfdhps* genes might be a step-wise process, two mutations at codon 59 of *pfdhfr* and codon 540 of *pfdhps* can accurately predict the presence of this quintuple mutant [26]. The molecular method for monitoring antifolate resistance in *P. falciparum* can thus

be simplified to detect the presence of these two mutations. This method has been shown to provide the best means of predicting clinical treatment outcomes in the patient population, which consists primarily of children from endemic areas of Africa [36]. In our study, either of these two mutations has exceeded 75% prevalence in the parasite populations, suggesting that at least 50% of the parasites carry these double mutations. Consistent with other genotype studies of *pfdhfr* from Kenyan isolates, we did not observe mutations at codon 164 [23,41,43], although McCollum et al. identified 164L mutation in several samples in western Kenya [21].

The causes of the malaria epidemics in the East African highlands are complex and could be the result of interactions between environmental changes, vectors and parasites. Antimalarial drug resistance has been invoked as a major factor [9], however the molecular epidemiology of drug resistance in these highlands is unknown. Mbaisi et al. [43] reported a significantly lower prevalence of mutations at codon 437 of the *pfdhps* gene and codons 86 and 1246 of the *pfmdr* gene in lowland (Kisumu) samples than in highland (Kericho, Magadi, and Entosopia) samples in western Kenya, whereas this trend was the opposite for the mutation at codon 436 of the *pfdhps* gene. In contrast, our study did not detect significant differences in frequency of mutations at 14 codons in four drug resistant genes between samples from lowland and highland areas in western Kenya, although the prevalence of mutations at codons 86 and 1246 of the *pfmdr* gene was higher in samples from the lowlands (Kombewa) than in those from the highlands (Kakamega and Kisii). This result suggests either a similar drug selection pressure or significant gene flow between lowland and highland parasite populations aided by human travel [44], as detected by microsatellite and merozoite surface protein 1 and 2 (*msh-1* and *msh-2*) [45].

Conclusion

Together with the evidence that there was no significance difference in the frequencies of key resistance-conferring mutations in *pfcr1*, *pfmdr1*, *pfdhps*, and *pfdhfr* genes between symptomatic and asymptomatic malaria infections in western Kenya highland, high frequencies of these mutations in symptomatic and asymptomatic infections suggest that drug resistance of malaria parasites may be an important contributor to malaria-induced morbidity and mortality. However, the role of drug resistance as a driving force for malaria outbreaks in the highlands has not been established. If drug resistance were the main driving force, the lowland and highland sites should expect similar epidemic pattern of malaria incidence. Moreover, drug resistance level should increase over time until a new antimalarial drug is adopted. Thus, the number of malaria patients would be expected to increase gradually over

time, but malaria incidence should not exhibit a large inter-annual variation. In contrast, dramatic fluctuations in malaria incidence in the African highlands were observed [9,46,47]. Significant association between climate variability and malaria incidence suggests that climate factors may play an important role in the East African highlands [47]. Further studies are required to examine the interactions between climate factors and drug resistance on malaria incidence in African highlands.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

DZ: Participated in the design of the study, conducted data collection, statistical analysis and drafting of the manuscript. YA: Conducted sample collection and helped with writing the manuscript. AG: Facilitated and conducted field sample collection. LC: Participated in the design of the study, interpretation of data and revising the manuscript. DM: Participated in experimental work and revising of the manuscript. GY: Conceived the study, participated in collection of samples, and participated in manuscript preparation. All authors read and approved the final manuscript.

Acknowledgements

The authors thank Hong Chen, Emmanuel A. Temu, Thomas Loescher, David Warhurst and two anonymous reviewers for constructive comments on the manuscript. The work was supported by NIH grants R01 AI50243, D43 TW01505, and R03 TW007360.

References

1. Snow RV, Guerra CA, Noor AM, Myint HY, Hay SI: **The global distribution of clinical episodes of *Plasmodium falciparum* malaria.** *Nature* 2005, **434**:214-217.
2. Sachs J, Malaney P: **The economic and social burden of malaria.** *Nature* 2002, **415**:680-685.
3. Garnham PCC: **Malaria epidemics at exceptionally high altitudes in Kenya.** *British Med J* 1945, **2**:45-47.
4. Roberts JMD: **The control of epidemic malaria in the highlands of western Kenya. Part I. Before the campaign.** *Am J Trop Med Hyg* 1964, **61**:161-168.
5. Lepers JP, Deloron P, Fontenille D, Coulanges P: **Reappearance of *falciparum* malaria in central highland plateaux of Madagascar.** *Lancet* 1988, **1**:586.
6. Some ES: **Effects and control of highland malaria epidemic in Uasin Gishu District, Kenya.** *East Afr Med J* 1994, **71**:2-8.
7. Lindsay SW, Martens WJ: **Malaria in the African highlands: past, present and future.** *Bull World Health Organ* 1998, **76**:33-45.
8. Malakooti MA, Biomndo K, Shanks GD: **Reemergence of epidemic malaria in the highlands of western Kenya.** *Emerg Infect Dis* 1998, **4**:671-676.
9. Hay SI, Cox J, Rogers DJ, Randolph SE, Stern DI, Shanks GD, Myers MF, Snow RV: **Climate change and the resurgence of malaria in the East African highlands.** *Nature* 2002, **415**:905-909.
10. Fogh S, Jepsen S, Efferson P: **Chloroquine-resistant *Plasmodium falciparum* in Kenya.** *Trans R Soc Trop Med Hyg* 1979, **73**:228-229.
11. Anabwani GM, Esamai FO, Menya DA: **A randomised controlled trial to assess the relative efficacy of chloroquine, amodiaquine, halofantrine and fansidar in the treatment of uncomplicated malaria in children.** *East Afr Med J* 1996, **73**(3):155-158.
12. Shretta R, Omumbo J, Rapuoda B, Snow RV: **Using evidence to change antimalarial drug policy in Kenya.** *Trop Med Int Health* 2000, **5**:755-764.

13. Amin AA, Walley T, Kokwaro GO, Winstanley PA, Snow RW: **Commentary: Reconciling national treatment policies and drug regulation in Kenya.** *Health Policy Plann* 2007, **22**:111-112.
14. Wellemans T, Plowe C: **Chloroquine-resistant malaria.** *J Infect Dis* 2001, **184**:770-776.
15. White NJ: **Antimalarial drug resistance.** *J Clin Invest* 2004, **113**:1084-1092.
16. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR: **Epidemiology of drug-resistant malaria.** *Lancet Infect Dis* 2002, **2**:209-218.
17. Hayton K, Su XZ: **Genetic and biochemical aspects of drug resistance in malaria parasites.** *Curr Drug Targets Infect Disord* 2004, **4**:1-10.
18. Sisowath C, Stromberg J, Martensson A, Msellem M, Obondo C, Björkman A, Gil JP: **In vivo selection of *Plasmodium falciparum* pfmrd1 86N coding alleles by artemether-lumefantrine (Coartem).** *J Infect Dis* 2005, **191**:1014-1017.
19. Ouellette M: **Biochemical and molecular mechanisms of drug resistance in parasites.** *Trop Med Int Health* 2001, **6**:874-876.
20. Peterson DS, Milhous WK, Wellemans TE: **Molecular basis of differential resistance to cycloguanil and pyrimethamine in *Plasmodium falciparum* malaria.** *Proc Natl Acad Sci USA* 1990, **87**:3018-3022.
21. McCollum AM, Poe AC, Hamel M, Huber C, Zhou Z, Shi YP, Ouma P, Vulule J, Boland P, Slutsker L, Barnwell JW, Udhayakumar V, Escalante AA: **Antifolate resistance in *Plasmodium falciparum*: multiple origins and identification of novel dhfr alleles.** *J Infect Dis* 2006, **194**:189-197.
22. Triglia T, Cowman AF: **The mechanism of resistance to sulfa drugs in *Plasmodium falciparum*.** *Drug Resist Update* 1999, **2**:15-19.
23. Wang P, Lee CS, Bayoumi R, Djimde A, Doumbo O, Swedberg G, Dao LD, Mshinda H, Tanner M, Watkins WM, Sims PF, Hyde JE: **Resistance to antifolate in *Plasmodium falciparum* monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a larger number of field samples of diverse origin.** *Mol Biochem Parasitol* 1997, **89**:161-177.
24. Curtis J, Duraisingh MT, Trigg JK, Mbwana H, Warhurst DC, Curtis CF: **Direct evidence that asparagine at position 108 of the *Plasmodium falciparum* dihydrofolate reductase is involved in resistance to antifolate drugs in Tanzania.** *Trans R Soc Trop Med Hyg* 1996, **90**:678-680.
25. Djimde A, Doumbo O, Cortese J, Kayentao K, Doumbo S, Diourte Y, Dicko A, Su XZ, Nomura T, Fidock DA, Wellemans TE, Plowe CV, Coulbaly D: **A molecular marker for chloroquine-resistant *falciparum* malaria.** *New Engl J Med* 2001, **344**:257-263.
26. Kublin JG, Dzinjalama FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RA, Rogerson SJ, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV: **Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of *Plasmodium falciparum* malaria.** *J Infect Dis* 2002, **185**:380-388.
27. Ndenga B, Githeko AK, Mushinzimana E, Munyekenye G, Atieli H, Wamai P, Mbogo C, Minakawa N, Zhou G, Yan G: **Population dynamics of malaria vectors in highlands and lowlands of western Kenya.** *J Med Entomol* 2006, **43**:200-206.
28. Wooden J, Kyes S, Sibley CH: **PCR and Strain Identification in *Plasmodium falciparum*.** *Parasitol Today* 1993, **9**:303-305.
29. Singh B, Bobogare A, Cox-Singh J, Snounou G, Abdullah MS, Rahman HA: **A genus and species-specific nested polymerase chain reaction malaria detection assay for epidemiologic studies.** *Am J Trop Med Hyg* 1999, **60**:687-692.
30. Schneider AG, Premji Z, Felger I, Smith T, Abdulla S, Beck HP, Mshinda H: **A point mutation in codon 76 of *pfert* of *P. falciparum* is positively selected for by Chloroquine treatment in Tanzania.** *Infect Genet Evol* 2002, **1**:183-189.
31. Flueck TP, Jelinek T, Kilian AH, Adagu IS, Kabagambe G, Sonnenburg F, Warhurst DC: **Correlation of in vivo-resistance to chloroquine and allelic polymorphisms in *Plasmodium falciparum* isolates from Uganda.** *Trop Med Int Health* 2000, **5**:174-178.
32. Duraisingh MT, Jones P, Sambou I, von Seidlein L, Pinder M, Warhurst DC: **The tyrosine-86 allele of the *pfmrd1* gene of *Plasmodium falciparum* is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin.** *Mol Biochem Parasitol* 2000, **108**:13-23.
33. Sisowath C, Ferreira PE, Bustamante LY, Dahlström S, Mårtensson A, Björkman A, Krishna S, Gil JP: **The role of *pfmrd1* in *Plasmodium falciparum* tolerance to artemether-lumefantrine in Africa.** *Trop Med Int Health* 2007, **12**:736-742.
34. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellemans TE: **Pyrimethamine and proguanil resistance-conferring mutations in *Plasmodium falciparum* dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa.** *Am J Trop Med Hyg* 1995, **52**:565-568.
35. Duraisingh MT, Curtis J, Warhurst DC: ***Plasmodium falciparum*: detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion.** *Exp Parasitol* 1998, **89**:1-8.
36. Kyabayinze D, Cattamanchi A, Kamya MR, Rosenthal PJ, Dorsey G: **Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with *falciparum* malaria.** *Am J Trop Med Hyg* 2003, **69**:247-252.
37. Yang Z, Zhang Z, Sun X, Wan W, Cui L, Zhang X, Zhong D, Yan G, Cui L: **Molecular analysis of chloroquine resistance in *Plasmodium falciparum* in Yunnan Province, China.** *Trop Med Int Health* 2007, **12**:1051-1060.
38. Temu EA, Kimani I, Tuno N, Kawada H, Minjas JN, Takagi M: **Monitoring chloroquine resistance using *Plasmodium falciparum* parasites isolated from wild mosquitoes in Tanzania.** *Am J Trop Med Hyg* 2006, **75**:1182-1187.
39. Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe PN, Djimde AA, Kouriba B, Taylor TE, Plowe CV: **Reemergence of chloroquine-sensitive *Plasmodium falciparum* malaria after cessation of chloroquine use in Malawi.** *J Infect Dis* 2003, **187**:1870-1875.
40. Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalama FK, Takala SL, Taylor TE, Plowe CV: **Return of chloroquine antimalarial efficacy in Malawi.** *N Engl J Med* 2006, **355**:1959-1966.
41. Nzila AM, Mberu EK, Sulo J, Dayo H, Winstanley PA, Sibley CH, Watkins WM: **Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in *Plasmodium falciparum*: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites.** *Antimicrob Agents Chemother* 2000, **44**:991-996.
42. Omar SA, Adagu IS, Gump DW, Ndaru NP, Warhurst DC: ***Plasmodium falciparum* in Kenya: high prevalence of drug-resistance-associated polymorphisms in hospital admissions with severe malaria in an epidemic area.** *Ann Trop Med Parasitol* 2001, **95**:661-669.
43. Mbaisi A, Liyala P, Eyase F, Achilla R, Akala H, Wangui J, Mwangi J, Osuna F, Alam U, Smoak BL, Davis JM, Kyle DE, Coldren RL, Mason C, Waters NC: **Drug susceptibility and genetic evaluation of *Plasmodium falciparum* isolates obtained in four distinct geographical regions of Kenya.** *Antimicrob Agents Ch* 2004, **48**:3598-3601.
44. Shanks GD, Hay SI, Omumbo JA, Snow RW: **Malaria in Kenya's western highlands.** *Emerg Infect Dis* 2005, **11**:1425-1432.
45. Zhong D, Afrane Y, Githeko A, Yang Z, Cui L, Menge DM, Temu EA, Yan G: ***Plasmodium falciparum* Genetic Diversity in Western Kenya Highlands.** *Am J Trop Med Hyg* 2007, **77**:1043-1050.
46. Snow RV, Craig M, Deichmann U, Marsh K: **Estimating mortality, morbidity and disability due to malaria among Africa's non-pregnant population.** *Bull World Health Organ* 1999, **77**:624-640.
47. Zhou G, Minakawa N, Githeko AK, Yan G: **Association between climate variability and malaria epidemics in the East African highlands.** *Proc Natl Acad Sci USA* 2004, **101**:2375-80.

Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-2334/8/105/prepub>